PharmacoEconomics & Outcomes News 365 - 1 Jun 2002 Europe lags behind the US in DM Europe lags behind the US in the area of disease management (DM), which, as a concept, differs between countries, says Dr Francesca Venturini of Pharmacy Interna, Verona, Italy. Dr Venturini interviewed ESCP * members from 13 countries across Europe to determine the transferability of DM programmes. Results showed that DM programmes were implemented to some degree in nine of the countries, while four countries had no such programmes in place. Among countries with existing DM programmes, they were consistently not in place in Italy and the UK, not available in primary care in The Netherlands, while DM programmes in Switzerland remained experimental. Dr Venturini notes that DM programmes are promoted by the government in most countries, despite a lack of government-funded healthcare systems in many cases. She adds that, ‘regardless of who is the major provider of health care, there is a need for continuity of care between hospital and primary care’. The study highlighted a lack of continuity of care, however, with seven of the 13 countries reporting no interaction between hospital and community pharmacists to discuss patient care. Also of note, Dr Venturini observed that, in some cases, pharmaceutical manufacturers were involved in DM management which suggests a potential conflict of interest. * European Society of Clinical Pharmacy How transferable are disease management programmes? Pharmaceutical Journal 268: 695, 18 May 2002 800907012 1 PharmacoEconomics & Outcomes News 1 Jun 2002 No. 365 1173-5503/10/0365-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Europe lags behind the US in DM

Download PDF Report

View
213
Download
1

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 365 - 1 Jun 2002

Europe lags behind the US in DMEurope lags behind the US in the area of disease

management (DM), which, as a concept, differsbetween countries, says Dr Francesca Venturini ofPharmacy Interna, Verona, Italy.

Dr Venturini interviewed ESCP* members from 13countries across Europe to determine the transferabilityof DM programmes. Results showed that DMprogrammes were implemented to some degree in nineof the countries, while four countries had no suchprogrammes in place. Among countries with existingDM programmes, they were consistently not in place inItaly and the UK, not available in primary care in TheNetherlands, while DM programmes in Switzerlandremained experimental. Dr Venturini notes that DMprogrammes are promoted by the government in mostcountries, despite a lack of government-fundedhealthcare systems in many cases. She adds that,‘regardless of who is the major provider of health care,there is a need for continuity of care between hospitaland primary care’. The study highlighted a lack ofcontinuity of care, however, with seven of the 13countries reporting no interaction between hospital andcommunity pharmacists to discuss patient care. Also ofnote, Dr Venturini observed that, in some cases,pharmaceutical manufacturers were involved in DMmanagement which suggests a potential conflict ofinterest.* European Society of Clinical Pharmacy

How transferable are disease management programmes? Pharmaceutical Journal268: 695, 18 May 2002 800907012